ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment
LONDON, /CNW/ -- A team of international scientists has made a major leap forward in diabetes research by successfully 3D printing functional human islets using a novel bioink. Presented today at the ESOT Congress 2025, the new technology could pave the way for more effective and less invasive treatment for people living with type 1 diabetes.
The breakthrough involved printing human islets – the insulin-producing clusters of cells in the pancreas – using a customised bioink made from alginate and decellularised human pancreatic tissue. This approach produced durable, high-density islet structures that remained alive and functional for up to three weeks, maintaining strong insulin responses to glucose and showing real potential for future clinical use.
Traditional islet transplants are typically infused into the liver, a process that can result in significant loss of cells and limited long-term success. In contrast, the 3D-printed islets were designed to be implanted just under the skin, a simple procedure requiring only local anaesthesia and a small incision. This minimally invasive approach could offer a safer and more comfortable option for patients.
"Our goal was to recreate the natural environment of the pancreas so that transplanted cells would survive and function better," explained lead author Dr. Quentin Perrier. "We used a special bioink that mimics the support structure of the pancreas, giving islets the oxygen and nutrients they need to thrive."
The bioprinted islets stayed alive and healthy, with over 90% cell survival. They responded better to glucose than standard islet preparations, releasing more insulin when it was needed. By day 21, the islets showed a stronger ability to sense and react to blood sugar levels – an important sign that they could work well after being implanted. The constructs maintained their structure without clumping or breaking down, overcoming a common hurdle in earlier approaches.
Additionally, the 3D-printed structures featured a porous architecture that enhanced the flow of oxygen and nutrients to the embedded islets. This design helped maintain cell health and promoted vascularisation, both of which are critical for long-term survival and function after transplantation.
"This is one of the first studies to use real human islets instead of animal cells in bioprinting, and the results are incredibly promising," noted Dr. Perrier. "We're getting closer to creating an off-the-shelf treatment for diabetes that could one day eliminate the need for insulin injections."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
18 hours ago
- Cision Canada
ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment
LONDON, /CNW/ -- A team of international scientists has made a major leap forward in diabetes research by successfully 3D printing functional human islets using a novel bioink. Presented today at the ESOT Congress 2025, the new technology could pave the way for more effective and less invasive treatment for people living with type 1 diabetes. The breakthrough involved printing human islets – the insulin-producing clusters of cells in the pancreas – using a customised bioink made from alginate and decellularised human pancreatic tissue. This approach produced durable, high-density islet structures that remained alive and functional for up to three weeks, maintaining strong insulin responses to glucose and showing real potential for future clinical use. Traditional islet transplants are typically infused into the liver, a process that can result in significant loss of cells and limited long-term success. In contrast, the 3D-printed islets were designed to be implanted just under the skin, a simple procedure requiring only local anaesthesia and a small incision. This minimally invasive approach could offer a safer and more comfortable option for patients. "Our goal was to recreate the natural environment of the pancreas so that transplanted cells would survive and function better," explained lead author Dr. Quentin Perrier. "We used a special bioink that mimics the support structure of the pancreas, giving islets the oxygen and nutrients they need to thrive." The bioprinted islets stayed alive and healthy, with over 90% cell survival. They responded better to glucose than standard islet preparations, releasing more insulin when it was needed. By day 21, the islets showed a stronger ability to sense and react to blood sugar levels – an important sign that they could work well after being implanted. The constructs maintained their structure without clumping or breaking down, overcoming a common hurdle in earlier approaches. Additionally, the 3D-printed structures featured a porous architecture that enhanced the flow of oxygen and nutrients to the embedded islets. This design helped maintain cell health and promoted vascularisation, both of which are critical for long-term survival and function after transplantation. "This is one of the first studies to use real human islets instead of animal cells in bioprinting, and the results are incredibly promising," noted Dr. Perrier. "We're getting closer to creating an off-the-shelf treatment for diabetes that could one day eliminate the need for insulin injections."
Cision Canada
2 days ago
- Cision Canada
RNAO celebrates Pride at events across Ontario
TORONTO, June 27, 2025 /CNW/ - Carrying colourful banners and dressed in their brightest attire, members of the Registered Nurses' Association of Ontario (RNAO) and members of its Rainbow Nursing Interest Group (RNIG) will continue an annual tradition of marching at several Pride events across the province this summer. "RNAO remains committed to supporting sexually and gender-diverse individuals, especially during Pride Month," says RNAO President NP Lhamo Dolkar. "Many of our members identify with the 2SLGBTQI+ community and/or provide care to community members. We are proud to march alongside them and will continue to advocate for safe, equitable and barrier-free care across all health sectors and settings. Our association values inclusivity and protecting the human rights of people of all sexual orientations, gender identities and gender expressions in Canada and around the world." RNAO members support 2SLGBTQI+ clients and colleagues in various roles throughout the health system on a daily basis, and the association has long advocated for equality. Registered nurses, nurse practitioners and nursing students across the province are determined to improve access to health services for equity-deserving communities, including Ontarians who identify as transgender. "RNAO is unwavering in its commitment to equity, diversity and inclusion (EDI). We are honoured to walk alongside our 2SLGBTQI+ family and friends again this year," says RNAO CEO Dr. Doris Grinspun. "At a time when we are witnessing a troubling rise in anti-2SLGBTQI+ sentiment and a broader backlash against diversity – including the recent decision by companies like Google, Home Depot, Nissan Canada and Clorox to withdraw their support for Pride – it is more important than ever to speak out, says Grinspun. "We call on all Canadians of conscience to expose corporate sponsors who backtrack on their EDI programs and retract their support at the first threat to their profits. These actions, influenced by President Donald Trump and Canadian far-right movements and fearmongering, are unacceptable and shameful," adds Grinspun. "We must not allow intimidation to roll back decades of progress. Nurses will continue to lead with compassion, evidence and courage to ensure the dignity, health and rights of every person are upheld," insists Dolkar. WHAT: Members of the Registered Nurses' Association of Ontario (RNAO) will march in Pride parades in communities across Ontario. HOW: Register online to attend one or more of the events. Reporters interested in interviewing an RNAO representative are encouraged to reach out to one of the contacts below. To learn more about RNAO's work related to 2SLGBTQI+ communities, visit the dedicated In Focus web page. The Registered Nurses' Association of Ontario (RNAO) is the professional association representing registered nurses, nurse practitioners and nursing students in Ontario. Since 1925, RNAO has advocated for healthy public policy, promoted excellence in nursing practice, increased nurses' contribution to shaping the health system, and influenced decisions that affect nurses and the public we serve. For more information about RNAO, visit or follow us on X (formerly Twitter), Facebook, Instagram and LinkedIn. SOURCE Registered Nurses' Association of Ontario
Cision Canada
2 days ago
- Cision Canada
Health Canada launches public consultation on proposed changes to increase oversight of precursor chemicals and drug equipment
OTTAWA, ON, June 27, 2025 /CNW/ - The Government of Canada is taking action to keep communities safe on both sides of the border. This includes detecting and disrupting the illegal fentanyl trade. Today, the Minister of Health, Marjorie Michel, launched a 45-day public consultation on proposed changes to how Canada regulates precursor chemicals and devices such as pill presses and encapsulators that could be used in the illegal production of drugs. The consultation is open until August 12, 2025. The public consultation will allow impacted stakeholders, such as regulated industries that use precursors for legitimate uses, pharmacies and individual pharmacists, to provide feedback on the proposed changes. These changes would strengthen controls around precursor chemicals and drug equipment to support law and border enforcement as they take action to stop their illegal importation and distribution. Quotes "Our government is acting to protect Canadians against illegal synthetic drugs like fentanyl. By working with the industry and our partners, we are making our streets safer." The Honourable Marjorie Michel Minister of Health "Keeping communities safe from the harms of illegal drugs is a top priority. Together with our Strong Borders bill, these proposed changes will give law enforcement and border officers stronger tools to stop the illegal production and trafficking of dangerous substances like fentanyl. We are committed to working with our partners to disrupt organized crime, further secure our borders and protect Canadians." The Honourable Gary Anandasangaree Minister of Public Safety "Step by step we are increasing pressure on organized crime groups and sending a clear message: Canada will not tolerate illegal drugs in our communities and at our borders. We will use every tool at our disposal to support law and border enforcement as they tackle the production and distribution of illegal drugs." Kevin Brosseau Fentanyl Czar Quick Facts Under the Controlled Drugs and Substances Act (CDSA), the Precursor Control Regulations (PCR) sets rules for the use of precursor chemicals. While some precursors have legitimate uses, they can also be used in the illegal production of controlled substances, like fentanyl and fentanyl analogues. In Canada, precursors are controlled under Schedule VI of the CDSA and are regulated under the PCR. To ensure that law and border enforcement have the tools they need to detect and address fentanyl and its precursors, the federal government is investing $78.7 million to expand Health Canada's laboratory and regulatory capabilities. Health Canada's Precursor Chemical Risk Management Unit provides better oversight into precursor chemicals and their distribution channels, and enhance monitoring and surveillance of illegal drug trends to enable timely law enforcement action. Health Canada is establishing a new Canadian Drug Analysis Centre that will allow for more specialized analysis of synthetic drug samples. The analysis will help determine how and where these substances were manufactured to support law enforcement and public safety partners to strategically target organized crime. Notice of Intent on this regulatory proposal to enhance oversight of precursor chemicals and drug equipment was open for public consultation from January 31 to March 3, 2025. 1S7Oa6kfqPnSMg%3D&rese SOURCE Health Canada (HC)
